According to a recent LinkedIn post from Segmed, the company is presenting new research at ECR 2026 on the use of large language models for CAD-RADS scoring in cardiac imaging. The study is described as a multicenter benchmarking effort, emphasizing evaluation across real-world clinical data from multiple institutions.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights Segmed’s view that clinically deployed AI must be validated on diverse, real-world imaging datasets to properly assess performance and limitations. This focus suggests the company is positioning its data platform and research capabilities as enablers of “trustworthy” clinical AI, which may be important for regulatory acceptance and adoption by hospital systems.
The session will be presented by Segmed’s Chief Scientific Officer and co-founder, which underscores leadership involvement in the company’s technical direction and scientific credibility. Active participation at a major radiology congress could strengthen Segmed’s brand among clinicians and researchers, potentially supporting future commercial partnerships and customer acquisition.
The post also notes the presence of the company’s CEO and broader team at the conference booth, indicating continued investment in business development and industry networking. For investors, this activity may signal a strategic push to align product offerings with emerging AI-in-radiology workflows and to capture demand from institutions seeking validated, data-driven AI solutions.